Company Filing History:
1 out of 832,843 Years Active: 2013
Title: Erik Hack - Innovator in Thrombus Prevention
Introduction
Erik Hack is a notable inventor based in Diemen, Netherlands. He has made significant contributions to the field of medicine, particularly in the area of thrombus prevention. His innovative work focuses on the use of anti-factor XI antibodies, which play a crucial role in inhibiting thrombus formation.
Latest Patents
Erik Hack holds a patent for the "Use of anti-factor XI antibodies for prevention of thrombus formation." This invention relates to binding molecules, such as antibodies, that specifically bind to plasma coagulation factor XI. These molecules inhibit factor XI activation and/or activity, providing methods for preventing or treating diseases and disorders mediated by factor XI activation. The beneficial effects of inhibiting factor XI are significant in the medical field.
Career Highlights
Throughout his career, Erik Hack has worked with various companies, including Argenx Bv. His expertise in the field has allowed him to contribute to advancements in medical research and therapeutic solutions.
Collaborations
Erik has collaborated with notable professionals in his field, including Christophe Blanchetot and Kevin Budding. These collaborations have further enhanced his research and development efforts.
Conclusion
Erik Hack's innovative work in the use of anti-factor XI antibodies represents a significant advancement in thrombus prevention. His contributions to the medical field highlight the importance of research and innovation in developing effective treatments.